Form 8-K - Current report:
SEC Accession No. 0001193125-24-100771
Filing Date
2024-04-18
Accepted
2024-04-18 16:06:15
Documents
19
Period of Report
2024-04-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d800395d8k.htm   iXBRL 8-K 134110
2 EX-99.1 d800395dex991.htm   iXBRL EX-99.1 223344
  Complete submission text file 0001193125-24-100771.txt   910950

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA teva-20240418.xsd EX-101.SCH 7978
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE teva-20240418_cal.xml EX-101.CAL 1373
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE teva-20240418_def.xml EX-101.DEF 16823
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20240418_lab.xml EX-101.LAB 32651
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20240418_pre.xml EX-101.PRE 27099
22 EXTRACTED XBRL INSTANCE DOCUMENT d800395d8k_htm.xml XML 199876
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 24854349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)